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TRPV1 is a nociceptive, Ca2-selective ion channel involved
in the development of several painful conditions. Sensitization
of TRPV1 responses by cAMP-dependent PKA crucially con-
tributes to the development of inflammatory hyperalgesia.
However, the pathways involved in potentiation of TRPV1
responses by cAMP-dependent PKA remain largely unknown.
Using HEK cells stably expressing TRPV1 and the  opioid
receptor, we demonstrated that treatment with the adenylate
cyclase activator forskolin significantly increased the multi-
meric TRPV1 species. Pretreatment with the  opioid receptor
agonist morphine reversed this increased TRPV1 multimeriza-
tion. FRET analysis revealed that treatment with forskolin did
not causemultimerization of pre-existingTRPV1monomers on
the plasma membrane and that intracellular pools of TRPV1
exist mostly as monomers in this model. This suggests that
increased TRPV1multimerization occurred from an intracellu-
lar store of inactive TRPV1 monomers. Treatment with forsko-
lin also caused an increase in TRPV1 expression on the plasma
membrane not resulting from increasedTRPV1 expression, and
this rapid TRPV1 translocation was inhibited by treatment with
morphine. Thus, potentiation of TRPV1 responses by cAMP-
dependent PKA involves plasma membrane insertion of func-
tional TRPV1 multimers formed from an intracellular store of
inactive TRPV1 monomers. This potentiation occurs rapidly
and can be dynamically modulated by activation of the opioid
receptor under conditionswhere cAMP levels are raised, such as
with inflammation. Increased translocation and multimeriza-
tion of TRPV1 channels provide a cellular mechanism for fine-
tuning of nociceptive responses that allow for rapidmodulation
of TRPV1 responses independent of transcriptional changes.
The ability to sensitize or desensitize painful stimuli is fun-
damental for survival. In inflammation, sensitization of periph-
eral nociception contributes to the development of hyperalge-
sia. Pro-inflammatory mediators including prostaglandins
mediate an increase in cellular cAMP levels, which in turn leads
to sensitization of nociception as a result of activation of cAMP-
dependent protein kinase (PKA)2 (1). Such sensitization may
involve the transient receptor potential vanilloid 1 (TRPV1) (2).
TRPV1 is a calcium-permeable ion channel that is activated
by the prototypical agonist capsaicin, the component that con-
veys the sensation of “heat” to chili peppers (3). Endogenous
TRPV1 activators include lipophilic arachidonic acid metabo-
lites such asN-arachidonoyl-dopamine and 12-hydroperoxyei-
cosatetraenoic acid (4, 5), but also heat and protons (3). TRPV1
and endovanilloid signaling are implicated in various inflam-
matory hyperalgesic conditions. The contribution of TRPV1 to
inflammatory hyperalgesia has been established through obser-
vations that TRPV1 antagonists can dose-dependently reverse
both thermal andmechanical inflammatory hyperalgesia (4, 5).
In addition, thermal inflammatory hyperalgesia is significantly
reduced in TRPV1 knock-out mice (6).
Several pro-inflammatory mediators and cytokines, includ-
ing prostaglandin E2, sensitize TRPV1 responses under inflam-
matory conditions (7). Moreover, the TRPV1 is sensitized
directly by cAMP-dependent PKA (8), making the TRPV1 a
direct molecular target for the development of inflammatory
hyperalgesia (2, 9). Although potentiation of TRPV1 responses
by cAMP-dependent PKA appears crucial in the development
of inflammatory hyperalgesia, the mechanisms underlying this
potentiation are not fully understood.
Peripheral sensitization of nociceptive responses represents
a cellular process to encourage rest and recovery after injury.
The ability to modify responses rapidly, without having to rely on
altering expression levels of nociceptive receptors, is essential for
rapid adaption to external circumstances. This system is exempli-
fied by the release of endogenous opioids from immune cells,
which affects analgesia in inflamed tissues (10), and the increased
effectiveness of exogenous opioids in inflammation (11). The
capacity for rapid fine-tuning and modulation of sensitized noci-
ception is further demonstrated by the ability of opioids to inhibit
TRPV1-mediated capsaicin responses potentiated by cAMP-de-
pendent PKA (12). To date, no mechanism has been proposed to
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grant REY016754A. This workwas also supported by anNHMRCDora Lush
Biomedical Research Scholarship (to I. V.) and the American Heart Associ-
ation (0665201Y) (to J. Z.). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must there-
fore be hereby marked “advertisement” in accordance with 18 U.S.C. Sec-
tion 1734 solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S5.
1 To whom correspondence should be addressed: School of Pharmacy, The
University of Queensland, St Lucia 4072, Australia. Tel.: 61-7-3365-1376;
Fax: 61-7-3365-1688; E-mail: p.cabot@uq.edu.au.
2 The abbreviations used are: PKA, cAMP-dependent kinase; TRPV1, transient
receptor potential vanilloid 1; HEK, human embryonic kidney cells; FRET,
fluorescence resonance energy transfer; MOP, opioid receptor; RTX, res-
iniferatoxin; PSS, physiological salt solution; FSK, forskolin;DRG,dorsal root
ganglion; PBS, phosphate-buffered saline; BSA, bovine serum albumin;
ANOVA, analysis of variance; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 28, pp. 19540–19550, July 11, 2008
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
19540 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 28•JULY 11, 2008
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
explain how TRPV1 sensitization by cAMP-dependent PKA can
be achieved in amanner that provides for rapid potentiationwhile
maintaining the capacity for dynamic modulation.
Here, we present evidence for a model that describes how, as
a consequence of activation of adenylate cyclase, an intracellu-
lar pool of inactive TRPV1 monomers is transported to the
plasma membrane where they function as TRPV1 multimers.
This mechanism incorporates 2-fold regulation involving both
alteredmultimerization and trafficking. It provides the basis for
rapid modulation of nociceptive TRPV1 responses and fine-
tuning of nociception. Modification of this pathway by the opi-
oid receptor agonist morphine can rapidly alter TRPV1 poten-
tiation and thus allows dynamic regulation of nociceptive
TRPV1 responses.
EXPERIMENTAL PROCEDURES
Microplate Reader Measurement of Intracellular Ca2
Responses in TRPV1/MOP HEK Cells—Double stable HEK293
cells expressing the  opioid receptor (MOP) and TRPV1
(TRPV1/MOP HEK cells) were generated as described (12).
TRPV1/MOP HEK cells were plated on PDL-coated 96-well
plates and loaded with the fluorescent calcium probe Fluo-
3-AM (6 M) as described (12). Cells were washed 2–3 times
with physiological salt solution (PSS; pH 7.4, composition KCl
5.9 mM, MgCl2 1.5 mM, NaH2PO4 1.2 mM, NaHCO3 5.0 mM,
NaCl 140.0 mM, glucose 11.5 mM, CaCl2 1.8 mM, and HEPES
10.0 mM) and incubated for 15–30 min with pretreatments as
appropriate. Preincubation steps and Ca2measurement were
carried out at 29 °C to avoid dye sequestration.
Changes in fluorescence after addition of capsaicin were
measured using a fluorescent multi-well plate reader
(NOVOstar, BMG Labtechnologies, Victoria, Australia) with
the excitation wavelength set at 485 nm and emission recorded
at 520 nm. As previously described, calcium responses were
represented as F/F values (12). Maximum F/F values were
used to fit a 4-parameter logistic Hill equation to the data using
GraphPad Prism (San Diego, CA, Version 4.03) to generate
dose-response curves. All experiments were designed to
include control experiments on the same plate as treated cells.
For calcium measurements using the FLIPRTETRA fluoro-
metric imaging plate reader (Molecular Devices, Sunnyvale,
CA), TRPV1/MOP HEK cells were plated on PDL-coated,
black-walled 96-well plates (Corning, Lindfield, NSW, Austra-
lia). After loading with Fluo-3 AM (6 M), cells were washed
three times with PSS or nominal calcium-free PSS (composi-
tion: KCl 5.9 mM, MgCl2 1.5 mM, NaH2PO4 1.2 mM, NaHCO3
5.0mM, NaCl 140.0mM, glucose 11.5mM, andHEPES 10.0mM)
as appropriate. Capsaicin and other reagents were injected
from 3–4 concentrated stock solutions prepared in PSS or
nominal calcium-free PSSwithmaximum final ethanol concen-
trations not exceeding 0.003%. Fluo-3-loaded cells were excited
at 470–495 nm, and emission at 515–575 nm was recorded
every second using a cooled CCD camera. For experiments
requiring no extracellular calcium, BAPTA (final concentration
100 M) was added 30 s prior to addition of capsaicin.
Whole Cell cAMP Accumulation Assay—TRPV1/MOP HEK
cells were harvested with Versene (Invitrogen, Mount Waver-
ley, Victoria, Australia) to avoid internalization of receptors.
Cells were resuspended with anti-cAMP acceptor bead mix
yielding final concentrations of 40,000 cells/well and 1 unit/well
of anti-cAMP acceptor beads. Cells were incubated for 15–30
minwith agonist in triplicate on 384-well plates (OptiPlate-384;
PerkinElmer Life Sciences, Rowville, Victoria, Australia) and
the reaction terminated by addition of lysis buffer containing
Streptavidin Donor beads (1 unit/well) and biotinylated cAMP
(1 unit/well). The plate was incubated under low light condi-
tions for 16 h, and the bioluminescence reaction measured
using the Envision Multilabel Plate Reader (PerkinElmer Life
Sciences).
SDS-PAGE andWestern Blotting—To assessmonomeric and
multimeric TRPV1 species, total cell protein was isolated and
separated by SDS-PAGE essentially as previously described
(13). Cells were grown to 80% confluency and incubated for
25–30 min at 37 °C with the appropriate treatments in PSS.
Cells were then immediately placed on ice, washed with ice-
cold phosphate-buffered saline (PBS; composition inmM: NaCl
137, KCl 2.7, NaH2PO4 10, KH2PO4 1.8) and dislodged with
ice-cold PBS. After centrifugation at 3,000 g for 10 min, cells
were resuspended in ice-cold PBS containing protease inhibi-
tors (Roche Applied Science, Castle Hill, NSW, Australia) and
sonicated briefly on ice. The supernatant was collected after
centrifugation at 1,000 g for 10 min at 4 °C and protein esti-
mation carried out using the Bio-Rad protein estimation kit.
Protein samples were analyzed on precast 4–20% iGel gradient
gels without SDS (Life Therapeutics, Frenchs Forest, NSW,
Australia). Total cell protein (20g)wasmixedwith 5 loading
buffer (composition: 365 mM Tris-HCl, pH 6.8, 37.5% glycerol,
0.02% bromphenol blue, and 10% SDS to yield SDS end concen-
trations of 2%) and denatured at 65 °C for 10min. Samples were
separated at 150 V for 60 min and transferred to nitrocellu-
lose membrane for 1 h at 300 mA on ice in transfer buffer
(composition: 25 mM Tris, 192 mM glycine, 15% methanol, pH
8.3). The nitrocellulose membrane was blocked overnight at
4 °C in blocking buffer (composition: 130 mM NaCl, 2.7 mM
KCl, 10 mM NaH2PO4, 1.8 mM KH2PO4, 0.1% Tween-20, and
10% low-fat skim milk powder) and incubated for 1 h at room
temperature with rabbit anti-rat TRPV1 antibody (1:5,000,
Santa Cruz Biotechnology). A monoclonal anti--actin anti-
body (1:20,000, clone AC-15, Sigma Aldrich) was also included
for visualization of -actin to serve as a loading control. After
washing in blocking buffer, the membrane was incubated for
1 h with anti-rabbit and anti-mouse horseradish peroxidase-
conjugated secondary antibodies (both 1:5,000; Zymed Labora-
tories Inc., Mount Waverley, Victoria, Australia). Blots were
developed using ECL Plus (GE Life Sciences, Rydalmere, NSW,
Australia) for visualization of chemiluminescence by exposure
to ECL Hyperfilm (GE Life Sciences). The optical density of
bands was determined using MetaMorph Imaging Software
(Version 6.2R5; Universal Imaging, Downington, PA).
[3H]Resiniferatoxin Binding—For preparation of total cell
membranes to assess binding of [3H]resiniferatoxin to the
TRPV1, cells were incubated at 37 °C in a 5% humidified CO2
incubator with the appropriate treatment for 20–30 min, sub-
sequently placed on ice, and washed 2–3 times with ice-cold
PBS. Cells were dislodged with a cell scraper and collected by
centrifugation at 3,000  g for 5 min. The cells were resus-
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pended in 1 ml of assay buffer (composition: 5 mM KCl, 5.8 mM
NaCl, 2mMMgCl2, 320mM sucrose, 10mMHEPES; pH7.4) and
sonicated briefly. After centrifugation at 1,000  g for 10 min,
the supernatant was collected, and after protein estimation
using a Bio-Rad protein assay kit, diluted to 20 g of protein/
200 l with assay buffer containing an additional 0.25 mg/ml
BSA.
Plasma membrane samples for [3H]resiniferatoxin binding
were prepared according to the manufacturer’s instructions
with a Plasma Membrane Protein Isolation kit (MBL Interna-
tional Corp, Woburn, MA) based on an aqueous two-phase
polymer system of dextran-polyethylene glycol, which isolates
plasma membrane proteins specifically with minimal contam-
ination from other intracellular membrane fractions (14, 15)
(supplemental Fig. S1). TRPV1/MOPHEK cells were incubated
with the appropriate treatments in PSS at 37 °C for 20–30min.
Cells were placed on ice immediately, washed with ice-cold
PBS, and 5–10 107 cells collected by centrifugation. The cell
pellet was resuspended with 1 ml of the homogenization buffer
included in the kit and briefly sonicated. The resulting homo-
genate was centrifuged at 700  g for 10 min at 4 °C, and the
resulting supernatant collected for protein estimation. For each
treatment group, an identical amount of supernatant protein
was utilized to isolate purified plasmamembrane fractions. The
plasma membrane protein pellet was collected by centrifuga-
tion at 44,800 g for 30min at 4 °C and resuspended in PBS for
protein estimation. For [3H]resiniferatoxin binding to the
TRPV1, the plasma membrane protein was diluted to 5 g of
plasma membrane protein/200 l with assay buffer containing
0.25 mg/ml BSA and used fresh.
Quantification of TRPV1 binding was performed by homol-
ogous competitive binding (16–19) in the presence of 50 pM
[3H]resiniferatoxin (PerkinElmer Life Sciences, 39.8 Ci/mmol)
and varying concentrations of unlabeled resiniferatoxin. Non-
specific binding was defined as occurring in the presence of 1
Mnon-radioactive resiniferatoxin. For total cell binding, 20g
of protein was used, while for plasma membrane binding, 5 g
of purified plasma membrane fractions were sufficient. Using
this protocol, nonspecific bindingwas generally below 10–20%,
as previously reported (18). Binding reactions were carried out
by incubation at 37 °C for 1 h and terminated by placing the
assay mixtures on ice. Bound and free fractions were separated
with a cell harvester on Whatman GF/B filters that had been
soaked in filter buffer (composition: 50 mM Tris-HCl, 0.1%
BSA, 0.5% polyethyleneimine; pH 7.4) at 4 °C for at least 1 h.
Samples were read on a liquid scintillation counter after incu-
bation of the filter papers with 3 ml of liquid scintillant
(OptiPhase HiSafe 3, PerkinElmer Life Sciences) at room tem-
perature for 10–14 h. The analysis of radioligand binding data
was performed using GraphPad Prism homologous competi-
tive binding analysis with one class of binding sites.
Determination of Cell Viability by MTS Assay—The viability
of TRPV1/MOP HEK cells was determined using the CellTiter
96 Aqueous One Solution Cell Proliferation Assay (Promega,
Annandale, NSW, Australia) according to the manufacturer’s
specifications. In brief, cells were grown to 80–90% conflu-
ency on 96-well plates and treated with varying concentrations
of dansylcadaverine in PSS for 30 min. After a wash with PSS,
cells were incubated with the MTS reagent for another 2 h at
37 °C in 5% CO2 and absorbance measured at 490 nm with a
Bio-Rad model 550 microplate reader.
Fluorescence Resonance Energy Transfer (FRET) Measure-
ments—FRET signals from murine homomultimeric TRPV1
channelswere determined as previously described (20). In brief,
HEK293 cells were transiently transfected with a C-terminal
Cerulean fluorescence protein-tagged TRPV1 construct
(TRPV1-CFP) and a C-terminal enhanced yellow fluorescence
protein-tagged TRPV1 construct (TRPV1-YFP) using Lipo-
fectamine 2000 (Invitrogen). Fluorescence imaging was carried
out at room temperature 1–2 days after transfection using a
fully automated inverted fluorescence microscope (Olympus
IX-81). For spectroscopic FRET measurements from the
plasma membrane, a spectrograph (Acton SpectraPro 2150i)
was used in conjunction with a Hamamatsu HQ CCD camera.
Spectroscopic emission data specifically from the plasmamem-
brane or the cytoplasmwas collected by recording fluorescence
intensity from the spectrograph slit location corresponding to
each cellular structure as previously described (21). FRET effi-
ciency was plotted as a function of the Cerulean to YFP fluores-
cence intensity ratio (Fc/Fy). Best fit FRET models were fitted
to the data as previously described (20) andwere represented as
solid or dotted lines.
Immunofluorescence—TRPV1/MOP HEK cells were plated
on 25-mmPDL-coated glass coverslips and grown to80–90%
confluence. Cells were treated for 30 min at 37 °C with the
appropriate reagents in PSS and placed immediately on ice to
minimize receptor internalization. Cells were washed twice in
ice-cold PBS before a light fix with methanol/acetone (1:1) at
20 °C for 30 min. After permeabilization with 0.2% Triton X
in PBS for 10min, cells were blocked by immersion in PBS with
3% BSA for 30 min. Rabbit anti-rat TRPV1 primary antibody
(1:100, Santa Cruz Biotechnology) was prepared in PBS con-
taining 3% BSA. After 1 h of incubation at room temperature,
cells were incubated with anti-rabbit fluorescein isothiocya-
nate-conjugated secondary antibody (1:300) under low light for
1 h. Cells were mounted using SlowFade AntiFade (Molecular
Probes). Randomly selected images were viewed on a Nikon
Eclipse TE 300 inverted fluorescentmicroscope (excitation 488
nm, emission 520 nm) and recorded with MetaFluor (Molecu-
lar Devices) imaging software. Corel Photo-Paint (Corel,
Ottawa, Ontario, Canada) was used for processing of images.
TRPV1 Expression in Calcium-rich Stores—As previously
described (22), to assess TRPV1 expression in calcium-rich
stores, the low affinity calcium probe Fura-FF was sequestered
into intracellular stores by loading TRPV1/MOP HEK cells
with Fura-FF-AM (12 M) for 2 h at 37 °C, followed by washing
with PSS for 15min at 37 °C. Coverslips were transferred to the
recording chamber of an inverted Nikon Eclipse TE 300 fluo-
rescent microscope and viewed under a Nikon 40/1.3 oil
immersion objective lens. Fluorescence signals from single cells
were ratio-imaged by recording emission intensity at 510 nm
from excitation at 340 and 380 nm. Ratios of F340/F380 were
depicted as pseudocolor images. Cells were then lightly fixed
with 4% paraformaldehyde for 20 min and stained for TRPV1
expression as described above.
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Assessment of TRPV1Multimers and Immunofluorescence in
DRG from Animals with Peripheral Inflammation—Ethical
approval was obtained from the University of Queensland Ani-
mal Ethics Committee and experiments carried out in accord-
ancewith guidelines of the Committee for Research and Ethical
Issues of the International Association for the Study of Pain.
Adult male Wistar rats (250–300 g) were kept in a controlled
environment at a temperature of 22 0.5 °C, relative humidity
of 40–60%, and a 12 h (6:30 AM to 6:30 PM) light-dark cycle
with free access to standard lab chow and tap water. To induce
peripheral inflammation, 100 l of Freund’s Complete Adju-
vant (FCA, Sigma) was injected subcutaneously into the right
hind paw under light isoflurane anesthesia. L5 DRGs ipsilateral
to the inflamed paw were isolated 6–7 days after induction of
inflammation. For analysis of TRPV1 multimerization in DRG
neurons, individual L5 DRG were placed immediately in ice-
cold PBS containing protease inhibitors (Roche Applied Sci-
ences), minced with surgical scissors and sonicated on ice. Pro-
tein samples were collected after centrifugation at 1,000 g for
10min and 20g of protein analyzed by SDS-PAGE andWest-
ern blotting as described above.
For immunofluorescence studies of plasma membrane
TRPV1 expression, L5 DRG contralateral and ipsilateral to the
inflamed paw were harvested and immediately fixed for 2–3 h
in ice-cold paraformaldehyde (4%). DRGs were then trans-
ferred to 0.32 M sucrose and cryoprotected at 4 °C for at least
24 h. Tissues were embedded in Tissue-Tek O.C.T. Com-
pound (Sakura Finetek, Torrance, CA), cut to 10-m cryostat
sections, and mounted on SuperFrost Ultra Plus tissue adhe-
sion slides (Menzel GmbH Co KG, Braunschweig, Germany)
before immunofluorescence labeling as described above.
Data Analysis—Unless otherwise states, all graphs are repre-
sentative of at least two to three independent experiments with
minimum n values for each treatment group being n  3.
Unless individual data points are shown, data are presented as
means S.E. of themean (S.E.). Asmentioned above, statistical
analysis and fitting of 4-parameter Hill equations were carried
out using GraphPad PrismVersion 4.03. Statistical significance
was defined as p  0.05 and determined using an unpaired,
two-tailed Student’s t test where appropriate. Calcium traces
were analyzed by statistical comparison of maximum F/F val-
ues using an unpaired, two-tailed Student’s t test with statistical
significance defined as p 0.05.
RESULTS
Capsaicin Responses Potentiated by cAMP-dependent PKA
Are Inhibited by Morphine—Potentiation of TRPV1-mediated
Ca2 responses to addition of varying concentrations of capsa-
icin was assessed after a short (15 min) incubation with 0.1%
DMSO (control) or forskolin (50 M, Fig. 1A). Treatment with
the adenylate cyclase activator forskolin leads to an increase in
cellular cAMP levels and resultant activation of cAMP-depend-
ent PKA. PKA-mediated phosphorylation of TRPV1 in turn
causes sensitization of TRPV1 responses (23). While cAMP
analogues acting directly at PKA lead to a similar sensitization,
opioids, by virtue of their antihyperalgesic activity resulting
from adenylate cyclase inhibition, are unable to prevent TRPV1
sensitization by direct PKA activators (12). Thus, to assess the
opioid-sensitive mechanisms involved in TRPV1 sensitization
by cAMP-dependent PKA, forskolin was used to potentiate
TRPV1 responses. Consistentwith previously described studies
(12), treatment with forskolin significantly increased TRPV1-
mediated capsaicin responses (Fig. 1, A and B, p 0.001). The
(MOP) agonist morphine inhibited this potentiation (Fig. 1B)
through inhibition of forskolin-stimulated cAMP production,
which was maximal at 1 M morphine, although reversal of
FIGURE 1. TRPV1-mediated capsaicin responses are potentiated by cAMP-dependent PKA. A, TRPV1/MOP HEK cells were treated with the PKA activator
forskolin (, FSK 50M) or PSS (F, no pretreatment), and calcium responses to the addition of capsaicinweremonitored. Treatmentwith forskolin significantly
(p 0.05) increased TRPV1-mediated calcium responses over the entire capsaicin concentration range. Addition of capsaicin (10 M) to non-transfected HEK
cells did not lead to an increase in intracellular Ca2 (, non-transfectedHEK cells). B, inset, inhibition of forskolin-stimulated cAMPaccumulation bymorphine
was assessed using an AlphaScreen cAMP assay. Treatment of TRPV1/MOP HEK cells with forskolin (50 M) increased cAMP levels compared with untreated
cells (E, no forskolin). Morphine dose-dependently inhibited cAMP accumulation stimulated by forskolin (50M) with amaximum effect at1Mmorphine.
B, calcium responses to addition of 300 nM capsaicin were assessed in cells loaded with the fluorescent calcium probe Fluo-3. Cells were treated with PSS (F,
control), forskolin (50M,, FSK), or forskolin andmorphine (1M,, FSKmorphine) as required. Pretreatment of forskolin-stimulated TRPV1/MOPHEK cells
with morphine () significantly (*, p 0.05) inhibited capsaicin-elicited calcium responses compared with cells treated with forskolin alone.
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forskolin-stimulated cAMPaccumulation bymorphinewas not
complete (Fig. 1B, inset). We then focused on assessing the
mechanism of potentiation of TRPV1 by forskolin.
Treatment of TRPV1/MOPHEKCells with the PKAActivator
Forskolin Increases TRPV1 Multimerization—Augmentation
of TRPV1 responses by forskolin (Fig. 1A) appears consistent
with an increase in functional TRPV1 channels. However, it is
unclear how forskolin could achieve an increase in functional
TRPV1 channels in a way that would be consistent with rapid
and dynamic regulation of nociceptive TRPV1 signaling. As
functional TRPV1 channels are proposed to exist in homomul-
timeric form (14, 19–23), one mechanism for cAMP-mediated
promotion of TRPV1 responses is assembly of pre-existing
plasma membrane TRPV1 monomers to form new functional
plasma membrane multimeric TRPV1 channels.
We assessed total cell TRPV1 multimerization by SDS-
PAGE under non-reducing conditions, as described previously
(13, 24). TRPV1 monomers and multimers are detectable by
SDS-PAGE under non-reducing conditions (13). Indeed, we
observed bands consistent with glycosylated and unglycosy-
lated TRPV1 monomers (97 and 113 kDa, respectively) as well
as a multimeric TRPV1 species (200 kDa) under these condi-
tions (Fig. 2A). This multimeric species represents a TRPV1
dimer, which is particularly stable, has previously been demon-
strated to parallel formation of the less stable tetramer, and can
be used to assess oligomerization of TRPV1 (13, 25).
TRPV1/MOP HEK cells were treated with 0.1% DMSO
(control), morphine (1 M), or forskolin (500 M, FSK) con-
taining in addition morphine (FSKmorphine) as appropri-
ate (Fig. 2, A and B). Treatment with forskolin significantly
(p  0.05 by ANOVA) increased TRPV1 multimer forma-
tion, while pretreatment with morphine reversed this
increase (Fig. 2, A and B).
Treatment with the Transglutaminase Inhibitor Dansylca-
daverine Inhibits Capsaicin Responses Potentiated by Forskolin—
To determine if TRPV1 functionality is affected when TRPV1
multimers are disrupted, we preincubated TRPV1/MOP HEK
cells with varying concentrations of the transglutaminase
inhibitor dansylcadaverine and assessed calcium responses to
the addition of 300 nM capsaicin in control and forskolin-stim-
ulated cells (Fig. 3A). Preincubation with dansylcadaverine at
previously reported concentrations (26) inhibited capsaicin
responses in control and forskolin-treated cells, consistent with
the functional form of the TRPV1 as a multimer (14, 20–23).
Forskolin-treated cells weremore sensitive to dansylcadaverine
(log EC50 (Control)3.185 0.027; log EC50 FSK3.269 0.013;
p  0.05). The inhibition of capsaicin responses by dansylca-
daverine was not due to impaired cell viability, globally
impaired calcium responses, or TRPV1 antagonism (Fig. 3,
B–D). There was no displacement of the radiolabeled TRPV1
agonist [3H]resiniferatoxin by unlabeled dansylcadaverine (100
M to 1.2 mM), indicating that the transglutaminase inhibitor
does not act as a competitive TRPV1 antagonist (Fig. 3B).
Preincubation with dansylcadaverine did not affect
responses to the calcium ionophore ionomycin (10 M, Fig.
3C), or cell viability over this period (Fig. 3D). Inhibition of
forskolin-stimulated capsaicin responses by dansylcadaver-
ine appears to be a consequence of inhibition of functional
TRPV1 multimer formation.
Forskolin Does Not Increase Multimerization of TRPV1
Monomers in the Plasma Membrane—Last, to assess the effect
of forskolin on changes in the proportion of plasma membrane
TRPV1 multimers and monomers, we quantified TRPV1 mul-
timerization utilizing a well characterized spectroscopy FRET
model (20) that allows quantification of FRET signals specifi-
cally from the plasma membrane. HEK cells were transiently
transfected with Cerulean fluorescence protein-tagged TRPV1
(TRPV1-CFP) and enhanced yellow fluorescence protein-
tagged TRPV1 (TRPV1-YFP) and the FRET signal determined
as previously described (20) prior to and after treatment with
forskolin (500M). No increase in FRET signal, a measure of de
novo formation of TRPV1 multimers from pre-existing plasma
membrane monomers, was detected (Fig. 4). Hence, increases
in cellular cAMP do not cause multimerization of TRPV1
monomers in the plasma membrane; rather, our results are
FIGURE 2. Activation of cAMP-dependent PKA by forskolin increases total cell TRPV1 multimerization. A, Western blot of TRPV1/MOP HEK cell protein
from cells treated with 0.1% DMSO (Control), morphine (1 M) and forskolin (FSK, 500 M) in the absence or presence of morphine (1 M, FSKmorphine).
Non-transfected HEK cells were used as a control, with sizemarkers in kDa shown on the right. Total cell lysates were prepared under non-reducing conditions
and analyzed by SDS-PAGE on 4–20% precast gradient gels. Similar results were obtained in four independent experiments. B, optical density of TRPV1
multimer bands were obtained usingMetaMorph (Molecular Devices), normalized to -actin and expressed relative to control. Treatment with forskolin (FSK,
black bar) significantly (*, p 0.05 compared with control by ANOVA) increased TRPV1 multimer density in total cell lysates.
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consistent with a model whereby forskolin increases plasmale-
mmal TRPV1 multimers from an internal pool of monomers.
TRPV1 Multimers Are Mainly Localized to the Plasma
Membrane—To determine if the intracellular pool of TRPV1
available for plasma membrane insertion was indeed in a mul-
timeric or monomeric state, we compared the relative propor-
tion of TRPV1 multimers and monomers in intracellular pools
and the plasma membrane. If forskolin was to promote the
assembly and rapid translocation of newly formed TRPV1mul-
timers to the plasma membrane from a pool of intracellular
TRPV1monomers, themajority ofTRPV1monomerswould be
found intracellularly, with a correspondingly large proportion
ofTRPV1multimers existing on the plasmamembrane.Assess-
ment of the FRET signal from the plasmamembrane and intra-
cellular compartments clearly demonstrated that TRPV1 mul-
timers occur mainly on the plasma membrane, while the
correspondingly lower FRET signal from intracellular compart-
ments is consistent with a higher proportion of TRPV1 mono-
mers (Fig. 5A). To assess the functionality of TRPV1 in these
internal pools, we determined the presence of TRPV1 on calci-
um-rich intracellular compartments and monitored calcium
release from stores in response to capsaicin. The low affinity
ratiometric calcium dye Fura-FF-AM (12 M) was sequestered
into intracellular stores. High Fura-FF fluorescence ratios
(F340/F380) indicative of high calcium levels were found in
similar patterns to TRPV1 immunofluorescence (Fig. 5B).
Although the TRPV1 was clearly expressed in calcium-rich
intracellular compartments, addition of capsaicin did not
increase cytosolic free calcium levels in the absence of extracel-
lular calcium (Fig. 5C). This is consistent with an intracellular
pool of inactive monomeric TRPV1 being available for plasma
membrane insertion, where it exists in a multimeric state.
Augmentation of TRPV1 Activity Is Associated with TRPV1
Translocation to the Plasma Membrane—Translocation of
TRPV1 channels to the plasma membrane was assessed in
TRPV1/MOP HEK cells treated with 0.1% DMSO (control),
forskolin (500 M, FSK), or morphine with forskolin (1 M,
FSKmorphine). As predicted by our model, treatment with
FIGURE 3. Dansylcadaverine inhibits TRPV1-mediated capsaicin responses potentiated by Forskolin. A, TRPV1/MOP HEK cells were treated with 0.1%
DMSO (control,E) or forskolin (500M, FSK,Œ) and calcium responses to addition of 300 nM capsaicinmonitored in the presence of varying concentrations of
the transglutaminase inhibitor dansylcadaverine. Treatment with dansylcadaverine significantly inhibited (p 0.01 by ANOVAwith Tukey’s postcomparison)
basal and forskolin-potentiated capsaicin responses. B, displacement of [3H]resiniferatoxin binding to TRPV1 by dansylcadaverine was assessed by exposing
TRPV1/MOPHEK total cell lysates to 50pM [3H]resiniferatoxin in thepresence of varying concentrations of unlabeleddansylcadaverine. Dansylcadaverine does
not act as a TRPV1 receptor antagonist, as [3H]resiniferatoxin bindingwas not affectedbydansylcadaverine (p	 0.05byANOVA).C, TRPV1/MOPHEK cellswere
treated with varying concentrations of dansylcadaverine for 30 min and calcium responses to the addition of ionomycin (10 M) was assessed using Fluo-3.
Treatment with dansylcadaverine did not significantly inhibit ionomycin responses (p	 0.05 by ANOVA) even at concentrations that completely abolished
capsaicin responses. D, cell viability after treatment with dansylcadaverine was determined using an MTS assay. TRPV1/MOP HEK cells were treated with
varying concentrations of dansylcadaverine for 30 min, and the number of viable cells determined by measuring absorbance at 490 nm. Treatment with
dansylcadaverine did not adversely affect cell viability (p 	 0.05 by ANOVA). Results are representative of 2–3 independent experiments with n  4–8 per
treatment.
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forskolin caused a marked translocation of TRPV1 immunore-
activity to the plasma membrane (Fig. 6A), resulting in distinct
membrane labeling. Pretreatment with morphine inhibited the
predominant plasma membrane TRPV1 expression pattern
and reversed TRPV1 labeling to mixed plasma membrane and
cytoplasmic localization (Fig. 6A). To exclude the possibility
that treatment with forskolin could increase de novo synthesis
of TRPV1 channels on the plasma membrane, we further
assessed TRPV1 binding density in isolated plasma membrane
protein fractions and total cell protein (Fig. 6, B and C) using
homologous competitive binding analysis.
Plasma membrane TRPV1 radioligand binding density in
TRPV1/MOP HEK cells treated with forskolin (500 M, FSK)
was significantly increased (p 0.05, Bmax FSK, 1284.6 419.2
pmol/mg protein) compared with control (Fig. 6B, Bmax con-
trol, 685.1  310 pmol/mg protein). In agreement with our
immunofluorescence studies, pretreatment with morphine
reversed this increased plasma membrane binding density
(Bmax FSKmorphine, 331.3  156.1 pmol/mg protein; Fig.
6B). Consistent with our model, total cell [3H]resiniferatoxin
binding was unaffected by treatment with forskolin or mor-
phine (Fig. 6C, p 	 0.05), indicating that the increase in
plasma membrane TRPV1 expression was due to transloca-
tion of TRPV1 channels rather than increased formation of
new TRPV1 protein.
TRPV1 Multimers and Plasma Membrane Expression in
Inflammation—We assessed whether two pools of TRPV1
(multimers and monomers) are present in vivo during inflam-
mation, a process where signaling through cAMP-dependent
PKA is increased (27).Western blot analysis demonstrated that,
as previously suggested, TRPV1 protein was present in
inflamed DRG in two distinct pools representing monomeric
and multimeric species (Fig. 7A). The presence of monomeric
and multimeric TRPV1 provides the basis for rapid dynamic
regulation of TRPV1 responses via themechanismswe propose
in addition to increased TRPV1 expression in inflammation
(28–31). Contribution of these pathways to in vivoTRPV1 sen-
sitization is also suggested by the increased TRPV1 plasma
membrane staining patterns in L5 DRG ipsilateral to the
inflamed hind paw (Fig. 7B).
DISCUSSION
Potentiation of TRPV1 responses by cAMP-dependent PKA
is crucial to the development of inflammatory hyperalgesia.
Although PKA consensus sites for TRPV1 have been identified
(32, 33), the molecular pathways leading to the rapid sensi-
tization of the receptor as a result of PKA-mediated phos-
phorylation are not fully understood. Our results propose a
newmechanismdescribinghowTRPV1potentiationbycAMP-
dependent PKA can be achieved rapidly without the need for
translational changes, while maintaining the capacity for
dynamic modulation of sensitized TRPV1 signaling. Our
results propose a mechanism for potentiation of TRPV1
responses by cAMP-dependent PKA incorporating both
increased TRPV1 translocation andmultimerization (Fig. 8).
The dynamic regulation of these pathways by opioids repre-
sents a cellular mechanism allowing for rapid modification
of the hyperalgesic or sensitized component of TRPV1
signaling.
The TRPV1 is a target for inflammatory signaling through
cAMP-dependent PKA. As an activator of adenylate cyclase
causing elevation of cellular cAMP levels, forskolin affects
potentiation of TRPV1 responses as a result of activation of
cAMP-dependent PKA (2, 23). Potentiation of TRPV1-medi-
ated capsaicin responses by forskolin is consistent with an
increase in functional TRPV1 channels and indeed, increased
TRPV1 expression occurs in inflammation (29, 31). However,
as the potentiation of capsaicin responses by forskolin occurs
rapidly, pathways other than increased transcription of TRPV1
must be involved and were assessed in this study.
The functional TRPV1 channel exists most likely as homo-
multimers, whereby monomeric TRPV1 subunits assemble in
tetrameric stoichiometry around the aqueous pore (13, 34). The
most compelling confirmation of the functional importance of
correct assembly of TRPV1 subunits arguably arises from the
observation that incorporation of a single dominant negative
mutant into the TRPV1 channel complex completely abolishes
capsaicin responses (34). Surprisingly, despite clear evidence
that TRPV1 multimerization is essential for channel function,
regulation of multimerization has not been described as a pos-
sible contributor to post-translational modification of TRPV1
function. An increase in TRPV1 multimerization would pro-
vide a cellular mechanism for achieving rapid modulation of
TRPV1 signaling without the need for altered transcription.
Indeed, we found that treatment with forskolin significantly
increased TRPV1multimers in total cell lysates, indicating that
the rapid potentiation of TRPV1 responses after treatmentwith
forskolin might involve the generation of new functional units
of TRPV1. Pretreatment withmorphine prevented a significant
increase in TRPV1 multimerization, providing evidence that
this system could present a pathway for rapid and dynamic
modulation of TRPV1 potentiation.
FIGURE 4. Treatment with forskolin does not affect TRPV1 monomer to
multimer ratio inplasmamembrane.HEK cellswere transiently transfected
with TRPV1-CFP and TRPV1-YFP and FRET efficiency measured from the
plasmamembraneof cells before (,dotted line) and after (f, solid line) treat-
ment with 500 M forskolin. Treatment with forskolin did not affect the total
plasma membrane FRET signal, indicating no change in the ratio of TRPV1
monomers to TRPV1 multimers in the plasma membrane. Each point repre-
sents measurements from a single cell.
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Activation of adenylate cyclase can increase transglutami-
nase activity and expression (32, 33), and TRPV1 cross-linking
has previously been demonstrated to involve transglutaminases
(13). Thus, we assessed the ability of forskolin to potentiate
TRPV1-mediated capsaicin responses under conditions
where TRPV1 multimers are disrupted. In accordance with
increased TRPV1 multimerization in response to forskolin,
capsaicin responses were sensitive to the transglutaminase
inhibitor dansylcadaverine, demonstrating the importance
of functional TRPV1 multimers in mediating TRPV1 poten-
tiation by forskolin.
To assess the effect of forskolin on changes in the proportion
of plasma membrane TRPV1 multimers and monomers, we
quantified TRPV1 multimerization by FRET. Increased mul-
timerization of TRPV1 monomers in a mixed population of
plasmamembrane TRPV1 subunits would result in an increase
in FRET. The FRET signal from the plasma membrane was not
affected by forskolin, indicating that the increase in TRPV1
multimers did not result from an increase in cross-linking of
pre-existing monomers in the plasma membrane. As FRET is
not affected by absolute fluores-
cence intensity and thus insensitive
to insertion of preformedmultimers
into the plasma membrane, this
would suggest that rather than pro-
moting multimerization of TRPV1
monomers in the plasma mem-
brane, forskolin might affect inser-
tion of TRPV1 multimers into the
plasma membrane. However, sim-
ple translocation of functional
TRPV1 multimers preformed in
intracellular stores would not only
be inconsistent with an overall
increase inTRPV1multimerization,
but in addition would likely lead to
major alteration of calcium homeo-
stasis in intracellular stores. An
intracellular store of inactive
TRPV1 monomers, however, would
provide a source of TRPV1 subunits
available for translocation to the
plasma membrane that would not
produce major disruptions in cal-
cium homeostasis. These mono-
mers are likely to be translocated to
the plasma membrane, where they
become inserted as functional
TRPV1 multimers, thus providing a
physiological mechanism for rapid
assembly of functional TRPV1
units. Consistent with this model,
the plasma membrane would be
expected to contain significantly
more TRPV1 multimers than the
intracellular space. This was indeed
shown to be the case, as evaluation
of the FRET signals from intracellu-
lar and plasma membrane regions revealed that TRPV1 mul-
timers are more abundant in the plasma membrane than in
intracellular regions.
Further functional evidence supporting our proposed model
stems from the observation that TRPV1 does not mediate sig-
nificant calcium release from intracellular stores at concentra-
tions that cause considerable influx of calcium through the
plasmamembrane. Several studies report TRPV1 expression in
intracellular structures such as the endoplasmic reticulum,
both in native aswell as overexpressed cell systems (31–33), and
TRPV1 expression in calcium-rich intracellular stores was con-
firmed here. If intracellular TRPV1 channels were indeed pre-
assembled as functional channels, this should translate into
effective release of calcium from intracellular stores upon chan-
nel activation, as TRPV1 agonists such as capsaicin are highly
lipophilic and readily cross the cellmembrane (35).While some
studies have attributed calcium release channel properties to
the TRPV1, calcium release from stores generally occurred at
significantly higher capsaicin concentrations than those
required to elicit calcium influx through plasma membrane
FIGURE 5. Functional TRPV1 multimers are located in the plasma membrane. A, FRET efficiency from the
plasma membrane and intracellular structures was determined in HEK cells transfected with TRPV1-CFP and
TRPV1-YFP. TRPV1 multimers, as assessed by FRET efficiency from plasma membrane, were increased in the
plasmamembrane comparedwith intracellular structures. Each point representsmeasurements from a single
cell with the same cell quantified for both intracellular (, dotted line, intra) and plasma membrane (f, solid
line, plasma) fluorescence. B, expression of TRPV1 on calcium-rich intracellular compartments was determined
by loading cells with the fluorescent calcium dye Fura-FF-AM. TRPV1 immunofluorescence (green, TRPV1) was
found in similar patterns to high Fura-FF emission ratios (red, Fura-FF, F340/F380) indicative of high calcium
levels. Scale bar, 20m. C, functionality of intracellular TRPV1 channels was assessed bymonitoring capsaicin-
induced calcium responses in nominal calcium-freemediumafter addition of the calcium chelator BAPTA (100
M). Although TRPV1 was clearly expressed in calcium-rich intracellular compartments, addition of capsaicin
did not elicit an increase in intracellular calcium in the absence of extracellular calcium (‚), in contrast to
capsaicin-elicited responses in the presence of 1.8 mM extracellular calcium (f).
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TRPV1 (31–33). Indeed, EC50 values of up to 13 M are
reported for capsaicin-mediated calcium release from intracel-
lular stores (36), while the corresponding EC50 for calcium
influx through plasma membrane TRPV1 is 30–40 nM (12,
37). Because high capsaicin concentrations are associated with
nonspecific effects including activation of phospholipase C
(38), mechanisms other than TRPV1 activation likely contrib-
ute to the release of calcium from intracellular stores in
response to high concentrations of capsaicin. Similarly, the
TRPM8 agonist menthol appears to release calcium from
the ER and Golgi via a TRPM8-independent mechanism (39).
We systematically compared capsaicin dose response curves in
the presence and absence of extra-
cellular calcium and found that,
consistent with a largely inactive
pool of TRPV1 in intracellular
structures, negligible store release
occurs in response to capsaicin con-
centrations that cause significant
calcium influx through the plasma
membrane. Indeed, an intracellular
reservoir of active TRPV1 channels
could be detrimental to cellular cal-
cium homeostasis given that
TRPV1 agonists are generally
lipophilic (35).
Promotion of TRPV1 multimer-
ization from intracellular mono-
mers by forskolin would require
rapid translocation of these TRPV1
channels to the plasma membrane.
Consistent with studies describing
mixed intracellular and plasma
membrane localization for TRPV1
in both native cells as well as over-
expressed systems (22, 31, 32), con-
trol cells displayed significant
expression of TRPV1 in intracellu-
lar structures, while some punctu-
ate TRPV1 localization was appar-
ent in the plasma membrane. In
contrast, treatment with forskolin
resulted in a striking shift in TRPV1
immunofluorescence to the plasma
membrane, resulting in a distinct
ring-like pattern. Pretreatment with
morphine demonstrated that this
translocation can be dynamically
modulated, as the predominant
plasma membrane localization of
TRPV1 was largely lost. Increased
TRPV1 translocation by forskolin
and inhibition thereof by morphine
was further confirmed by quantifi-
cation of [3H]resiniferatoxin bind-
ing to purified plasma membrane
fractions. These findings demon-
strate that themechanisms underly-
ing rapid potentiation of TRPV1-mediated capsaicin responses
by the adenylate cyclase activator forskolin can be dynamically
modulated by morphine, an observation that could be of par-
ticular relevance to inflammatory hyperalgesia. Such opioid-
mediated modulation of TRPV1 multimerization and traffick-
ing could, in addition to effects of opioids on other
inflammatory mediators (40–46), also contribute to the
enhanced anti-nociceptive effect of opioids in inflammation.
The exact pathways involved in trafficking and multimeriza-
tion of TRPV1 by cAMP-dependent PKA remain to be eluci-
dated. Notably, both PKAphosphorylation sites as well as puta-
tive SNARE interaction sites are located on the N-terminal of
FIGURE 6. Plasma membrane TRPV1 localization is increased by treatment with forskolin and reversed
by morphine. A, treatment with forskolin caused translocation of TRPV1 immunoreactivity to the plasma
membrane. TRPV1/MOP HEK cells were treated with 0.1% DMSO (Control), forskolin (500 M, FSK), or forskolin
and morphine (1 M, FSKmorphine) and stained for TRPV1 expression (green). Treatment with forskolin
caused a marked shift in TRPV1 localization to plasma membrane-dominant expression (FSK). Pretreatment
with morphine reversed TRPV1 staining to mixed plasma membrane and cytosolic pattern (FSKmorphine).
Scale bar, 20m. Data are representative of three independent experiments. A, inset, magnified view (1.6) of
cells indicated by an arrow. B, plasmamembrane TRPV1 binding density is increased by treatmentwith forsko-
lin. Quantification of plasma membrane TRPV1 protein was assessed by [3H]RTX binding to purified plasma
membrane samples. TRPV1/MOP HEK cells were treated with 0.1% DMSO (control, E) or forskolin (500 M, Œ)
containing in additionmorphine (1M) as required (FSKmorphine,F), and [3H]resiniferatoxin displacement
from purified plasma membrane preparations was assessed in the presence of various concentrations of
unlabeled resiniferatoxin. Treatment with forskolin increased TRPV1 binding density in plasma membrane
fractions compared with control, and this increase was reversed by pretreatment with morphine. Data are
presentedasmeanS.E. from five independent experiments.C, total cell TRPV1bindingdensity is not affected
by treatmentwith forskolin. [3H]Resiniferatoxindisplacement fromtotal cell proteinpreparationswas assessed
in TRPV1/MOP HEK cells treated with 0.1% DMSO (control, E) or forskolin (500 M, Œ) containing in addition
morphine (1 M) as required (FSKmorphine, F). Treatment with forskolin did not affect total cell TRPV1
binding density. Data are presented as mean S.E. from five independent experiments.
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TRPV1 (8, 47, 48), such that phosphorylation of TRPV1 by PKA
could lead to enhancement of these exocytosis pathways
through to-date unknown mechanisms. Indeed, PKA-depend-
ent trafficking pathways have been reported for a number of
receptors and ion channels including the chloride-selective
anion channel CFTR and AMPA receptor (49, 50). Alterna-
tively, increased multimerization and translocation of TRPV1
could occur as a downstream result of PKA-mediated phospho-
rylation of other effectors rather
than as a direct result of phospho-
rylation of TRPV1 by PKA. Indeed,
TRPV1 has been reported to bind to
several proteins involved in recep-
tor trafficking, including Snapin and
synaptotagmin IX as well as eferin
(48, 51). The function of these pro-
teins in turn can be affected byPKA-
mediated phosphorylation (52). As
several other proteins have been
reported to regulate trafficking of
various trp channels (53), the exact
pathways involved in PKA-medi-
atedTRPV1 trafficking remain to be
identified.
Similarly, in addition to increased
transglutaminase activity and
expression as a result of activation of adenylate cyclase (32, 33),
other pathways not implicated to date may be involved in
increased multimerization of TRPV1 by cAMP-dependent
PKA. Speculatively, TRPV1 multimerization might occur in
lipid rafts in the plasma membrane due to the presence of to-
date unidentified accessory proteins. Indeed, depletion of cho-
lesterol can inhibit TRPV1 function and plasma membrane
expression (54), supporting the notion that correct TRPV1
assembly to functionalmultimers occurs in discreet areas of the
plasmamembrane. Once the exact pathways involved are iden-
tified, these would present themselves as therapeutic targets to
modulate TRPV1-mediated hyperalgesia.
In conclusion, our findings point toward a mechanism
that allows for rapid and dynamic modulation of TRPV1
responses. Insertion of functional TRPV1multimers into the
plasma membrane from an intracellular store of inactive
monomers as a consequence of activation of cAMP-depend-
ent PKA allows for rapid potentiation and modulation of
TRPV1 responses and conveys the additional advantage of
minimizing disruption of intracellular calcium stores. This
model further extends the complexity of cellular regulation
of TRPV1 potentiation beyond the simple increase in traf-
ficking that is suggested to mediate TRPV1 sensitization by
protein kinase C (37–39). In addition, this system provides
the capacity for rapid potentiation of TRPV1 responses with-
out having to rely on transcriptional changes. Modification
of the cellular mechanisms that lead to multimerization of
TRPV1 channels and insertion of functional channels into
the plasma membrane provides an endogenous pathway for
adjusting hyperalgesia, without altering nociception itself.
The propensity for dynamic regulation of potentiated
TRPV1 responses is demonstrated by the ability of morphine
to inhibit forskolin-mediated potentiation of TRPV1
responses by modulating TRPV1 multimerization and
plasma membrane trafficking. This model may be of partic-
ular relevance to inflammation, where cellular cAMP levels
are elevated, and the resultant increased activity of cAMP-
dependent PKA contributes to the development of hyper-
algesia (7, 27), but may also apply to other potentiation
pathways.
FIGURE 7. TRPV1 expression in inflammation. A, inflammation was induced in adult male Wistar rats by
injectionof Freund’s CompleteAdjuvant. Protein fromL5DRG ispsilateral to the inflamedpawwas analyzedby
SDS-PAGE. TRPV1monomers andmultimers occur in inflamed DRG, providing the basis for increasedmultim-
erization in inflammation. B, TRPV1 expression in L5 DRG ipsilateral and contralateral to the inflamed paw
shows increased plasmamembrane localization of TRPV1 in inflamedDRG comparedwith non-inflamedDRG.
Data are representative of five animals with peripheral hind paw inflammation. Arrows point to TRPV1 immu-
nofluorescence localized to the plasma membrane.
FIGURE 8. Schematic representation ofmechanisms involved in poten-
tiation of TRPV1 responses by forskolin. An intracellular pool of mono-
meric TRPV1 subunits becomes multimerized and inserted into the
plasma membrane as functional TRPV1 multimers in response to activa-
tion of adenylate cyclase by forskolin. This increase in functional TRPV1
channels located on the plasma membrane translates to potentiation of
TRPV1-mediated capsaicin responses by forskolin. Morphine, via inhibi-
tory action on adenylate cyclase, can dynamically modulate TRPV1 mul-
timerization and trafficking, thus resulting in inhibition of forskolin-stim-
ulated TRPV1 responses. An intracellular store of TRPV1 monomers allows
for rapid modulation of TRPV1 signaling independent of transcriptional
changes without disruption to intracellular calcium homeostasis by
effecting calcium store depletion.
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Supplemental Data 
 
 
Supplementary Figure 1 
Analysis of purity of plasma membrane and non-plasma membrane fractions. 
Plasma membrane and remaining non-plasma membrane fractions were prepared from 
HEK cells using the plasma membrane isolation kit (MBL International Corp) according 
to manufacturer’s instructions. Purity of both fractions was analysed by assessing 
expression of plasma membrane proteins E-Cadherin (rabbit E-Cadherin antibody, 
1:3000, a kind gift from Alpha Yap, Institute of  Molecular Biosciences, Queensland, 
Australia) and PMCA4 (mouse anti-PMCA4 antibody JA9, 1:1000, Abcam) as well as 
the endoplasmic protein SERCA2 (mouse anti-SERCA2 antibody MA3-910, 1:1000, 
Affinity Bioreagents). Optical density of bands was determined using GraphPad Prism 
and expressed as % of the combined signal from the plasma membrane and remaining 
non-plasma membrane fractions. 
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Supplementary Figure 2 
Capsaicin-induced Ca2+ responses in double stable TRPV1/MOP HEK cells are 
mediated through TRPV1.  
Non-transfected HEK cells were loaded with the fluorescent Ca2+ dye Fluo-3 and 
responses to addition of 10 μM capsaicin monitored using the fluorescent plate reader 
NOVOstar. Non-transfected HEK cells did not respond with an increase in intracellular 
Ca2+ to capsaicin, even when very high (10 μM) capsaicin concentrations were applied. 
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Supplementary Figure 3 
Treatment with forskolin dose-dependently increases cAMP accumulation in 
TRPV1/MOP HEK cells. 
cAMP accumulation in response to incubation with varying concentrations of forskolin 
and constant concentrations of IBMX (100 µM) was assessed in TRPV1/MOP HEK cells 
using an AlphaScreen cAMP accumulation assay. Data are presented as mean ± SEM 
with n = 3. 
 
  
Supplementary Figure 4 
TRPV1 immunofluorescence and DAPI stain in untransfected HEK cells. 
Non-transfected HEK cells and TRPV1/MOP HEK cells were plated on PDL-coated 
glass coverslips, fixed with methanol-acetone (1:1) and incubated with anti-TRPV1 
antibody (1:100, Santa Cruz) followed by anti-rabbit FITC conjugated secondary 
antibody (1:300, Zymed) and DAPI (300 nM) for visualisation of nuclei. Minimal non-
specific immunofluorescence is visible in non-transfected HEK cells. Scale bar, 20 µm. 
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Supplementary Figure 5 
Ca2+ responses in TRPV1/MOP HEK cells after pre-incubation of capsaicin with 
dansylcadaverine  
TRPV1/MOP HEK cells were loaded with the fluorescent Ca2+ dye Fluo-3 and responses 
to addition of 300 nM capsaicin (Capsaicin, ■) were monitored using the fluorescent 
plate reader FLIPR. Pre-incubation of capsaicin with dansylcadaverine (1 mM; 
Capsaicin+Dansylcadaverine, ○) for 10 minutes did not decrease capsaicin-induced Ca2+ 
responses. Addition of dansylcadaverine alone did not affect Ca2+ responses 
(Dansylcadaverine, ▼). Data are presented as mean ± SD from n = 28 wells. 
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